Key result
Poor coronary collateralization was an independent predictor for time to major adverse cardio-cerebral events (HR 2.155) in non-diabetic patients after successful CTO-PCI, but not in those with type 2 diabetes.
Why the study?
The prognostic role of coronary collaterals in patients with type 2 diabetes mellitus after successful PCI for chronic total occlusion needed to be assessed.
Does good coronary collateralization improve long-term clinical outcomes and left ventricular function in patients with and without type 2 diabetes after successful recanalization of chronic total occlusion?
Observational (n=533)
No
Does good coronary collateralization improve long-term clinical outcomes and left ventricular function in patients with and without type 2 diabetes after successful recanalization of chronic total occlusion?
Good coronary collateralization is associated with improved long-term clinical outcomes after successful CTO-PCI in non-diabetic patients, but this protective effect is attenuated or absent in patients with type 2 diabetes.
Answers are grounded in this paper and cite their sources.
Poor collateralization predicts MACCE only in non-diabetics post-CTO-PCI; leaves open diabetes modification and need for prospective validation.
BACKGROUND: To assess the prognostic role of coronary collaterals in patients with type 2 diabetes mellitus (T2DM) after successful percutaneous coronary intervention (PCI) for chronic total occlusion (CTO). METHODS: Coronary collateralization was graded according to Rentrop scoring system in 198 type 2 diabetic patients and 335 non-diabetics with stable angina undergoing PCI for at least one CTO lesion. Left ventricular ejection fraction (LVEF) was determined and major adverse cardio-cerebral events (MACCE) were recorded during follow-up. RESULTS: Poor collateralization was more common in patients with T2DM than in non-diabetics (40% vs 29%, p = 0.008). At 13.5 ± 4.1 months, the rate of composite MACCE (17.3% vs 27.6%, p = 0.034) and repeat revascularization (15.2% vs 25.5%, p = 0.026) was lower and the increase in LVEF (3.10% vs 1.80%, p = 0.024) was greater in patients with good collaterals than in those with poor collaterals for non-diabetic group. The associations were in the same direction for T2DM group (35% vs 44%; 30% vs 36%; 2.14% vs 1.65%, respectively) with a higher all-cause mortality in diabetic patients with poor collaterals (p = 0.034). Multivariable Cox proportional hazards analysis showed that coronary collateralization was an independent factor for time to MACCE (HR 2.155,95% CI 1.290-3.599, p = 0.003) and repeat revascularization (HR 2.326, 95% CI 1.357-3.986, p = 0.002) in non-diabetic patients, but did not enter the model in those with T2DM. CONCLUSIONS: T2DM is associated with reduced coronary collateralization. The effects of the status of coronary collateralization on long-term clinical outcomes and left ventricular function appear to be similar in size in type 2 diabetic patients and non-diabetics after successful recanalization of CTO.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2020) conducted an observational in Chronic total occlusion in patients with stable angina (n=533). Poor coronary collateralization vs. Good coronary collateralization was evaluated on Composite major adverse cardio-cerebral events (MACCE) in non-diabetic patients (HR 2.155, 95% CI 1.290-3.599, p=0.003). Poor coronary collateralization was an independent predictor for time to major adverse cardio-cerebral events (HR 2.155) in non-diabetic patients after successful CTO-PCI, but not in those with type 2 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: